Cytarabine
- Generic Name
- Cytarabine
- Brand Names
- Cytosar, Vyxeos
- Drug Type
- Small Molecule
- Chemical Formula
- C9H13N3O5
- CAS Number
- 147-94-4
- Unique Ingredient Identifier
- 04079A1RDZ
- Background
A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)
- Indication
For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.
Cytarabine is indicated in combination with daunorubicin for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Acute Promyelocytic Leukemia, Meningeal leukemia, Metastatic Malignant Neoplasm to the Leptomeninges, Non-Hodgkin's Lymphoma (NHL), Treatment-Related Acute Myeloid Leukemia, Blast phase Chronic myeloid leukemia
- Associated Therapies
- -
HDM201 Added to CT in R/R or Newly Diagnosed AML
- First Posted Date
- 2018-11-30
- Last Posted Date
- 2020-01-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT03760445
Acalabrutinib Plus RICE for Relapsed/Refractory DLBCL
- First Posted Date
- 2018-11-09
- Last Posted Date
- 2022-07-22
- Lead Sponsor
- Swedish Medical Center
- Target Recruit Count
- 47
- Registration Number
- NCT03736616
- Locations
- 🇺🇸
Swedish Cancer Institute, Seattle, Washington, United States
Prexasertib in Combination With MEC in Relapsed/Refractory AML and High Risk MDS - a Phase I Trial
- Conditions
- Interventions
- First Posted Date
- 2018-11-08
- Last Posted Date
- 2019-06-12
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 2
- Registration Number
- NCT03735446
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
Pinometostat With Standard Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and MLL Gene Rearrangement
- Conditions
- Interventions
- First Posted Date
- 2018-10-30
- Last Posted Date
- 2024-06-11
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 6
- Registration Number
- NCT03724084
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
🇺🇸Yale University, New Haven, Connecticut, United States
Early Systemic Central Nervous System Prophylaxis in Diffuse Large B-cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2018-10-25
- Last Posted Date
- 2020-04-13
- Lead Sponsor
- Brown University
- Registration Number
- NCT03719560
- Locations
- 🇺🇸
Roxanne Wood, Providence, Rhode Island, United States
Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients with Newly Diagnosed Mantle Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2018-10-18
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 51
- Registration Number
- NCT03710772
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Venetoclax in Combination With Intensive Induction and Consolidation Chemotherapy in Treatment Naïve AML
- Conditions
- Interventions
- First Posted Date
- 2018-10-17
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 64
- Registration Number
- NCT03709758
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
Daunorubicin and Cytarabine With or Without Uproleselan in Treating Older Adult Patients With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy
- First Posted Date
- 2018-10-10
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 670
- Registration Number
- NCT03701308
- Locations
- 🇺🇸
Mercy Health - Perrysburg Hospital, Perrysburg, Ohio, United States
🇺🇸University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
🇺🇸Community Cancer Institute, Clovis, California, United States
Selinexor (KPT-330) Plus FLAG-Ida for the Treatment of Relapsing/Refractory AML
- Conditions
- Interventions
- First Posted Date
- 2018-09-07
- Last Posted Date
- 2020-05-20
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 16
- Registration Number
- NCT03661515
- Locations
- 🇪🇸
Hospital San Pedro de Alcántara,, Cáceres, Spain
🇪🇸Hospital la Fe, Valencia, Spain
🇪🇸Hospital Germans Tries i Pujol, Badalona, Badalona, Spain
Phase 1 Study of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-08-31
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 21
- Registration Number
- NCT03654716
- Locations
- 🇺🇸
UCSF Benioff Children's Hospital, San Francisco, California, United States
🇺🇸Texas Children's Hospital, Baylor College of Medicine, Houston, Texas, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.